Why Is BioMarin Stock Trading Higher On Thursday?

On Wednesday, BioMarin Pharmaceutical Inc. BMRN reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents.The company reported sales of $747.31 million, beating the consensus of$713.44 million. Total Revenues increased 16% year over year, driven by Voxzogo contributions from new patient starts in all regions.In the quarter, revenues from BioMarin's Enzyme Therapies increased 9%, driven by increased patient demand in all regions and the timing ...